Gregory Bjorklund, PA
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Sanofi at 39.5% of the total. Among medical clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $133.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$18K
- EMD Serono, Inc.$10K
- Biogen$8K
- E.r. Squibb & Sons, L.L.C.$4K
- Bristol Myers Squibb$2K
- TG Therapeutics, Inc.$2K
- plus $2K from 19 others
What the payments were for
- Consulting fees$24,05851%
- Speaking & faculty fees$12,39927%
- Travel & lodging$1,6123%
- Food & beverage$8,61318%
- Education$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 43 | $18,449 |
| EMD Serono, Inc. | 105 | $10,252 |
| Biogen | 39 | $8,235 |
| E.r. Squibb & Sons, L.L.C. | 7 | $3,690 |
| Bristol Myers Squibb | 33 | $2,149 |
| TG Therapeutics, Inc. | 21 | $1,743 |
| Novartis | 47 | $1,151 |
| ANI Pharmaceuticals, Inc. | 10 | $193 |
| Genentech USA, Inc. | 10 | $184 |
| UCB, Inc. | 6 | $143 |
| AstraZeneca | 7 | $128 |
| Acorda Therapeutics, Inc | 6 | $101 |
| Argenx US, Inc. | 4 | $65 |
| Greenwich Biosciences, Inc. | 1 | $49 |
| Amgen | 2 | $40 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Eisai Inc. | 1 | $24 |
| Amylyx Pharmaceuticals, Inc. | 1 | $20 |
| Invivyd Inc | 1 | $18 |
| Averitas Pharma Inc. | 1 | $16 |
| Springworks Therapeutics, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Pfizer | 1 | $13 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,745 in reported general payments places this provider in the 95th percentile of 51 medical providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 67 | $589,596 |
| CopaxoneGlatiramer Acetate | 61 | $442,726 |
| GilenyaFingolimod Hcl | 26 | $274,227 |
| Radicava OrsEdaravone | 12 | $154,354 |
| RebifInterferon Beta-1a/Albumin | 11 | $113,725 |
| TecfideraDimethyl Fumarate | 12 | $113,044 |
| Teriflunomide | 44 | $102,622 |
| Dalfampridine ErDalfampridine | 98 | $44,707 |
| KeppraLevetiracetam | 50 | $41,454 |
| NuedextaDextromethorphan Hbr/Quinidine | 44 | $34,167 |
| FingolimodFingolimod Hcl | 74 | $33,147 |
| Aimovig AutoinjectorErenumab-Aooe | 29 | $28,027 |
| NeurontinGabapentin | 17 | $24,244 |
| TopamaxTopiramate | 12 | $11,579 |
| MyrbetriqMirabegron | 24 | $10,561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisGilenya | $1,151 | $274,22726 claims |
| EMD Serono, Inc.Rebif | $10,252 | $113,72511 claims |
| BiogenTecfidera | $8,235 | $113,04412 claims |
| PfizerDilantin, Dilantin | $13 | $11,30499 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 51 medical providers in North Dakota.
Other medical in Fargo
- Angela WagnerFargo$4K
- Debra AndvikFargo$3K
- David TullarFargo$2K
- Catherine GarveyFargo$2K
- Melissa ChristensenFargo$2K
- Dacia EngbergFargo$1K
- Kathryn GrayFargo$1K
- Jamie BrownFargo$968
- Susan HansonFargo$709
- Yan TeschFargo$509
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.